Suppr超能文献

经皮冠状动脉介入治疗与最佳药物治疗慢性完全闭塞的结局:一项综合荟萃分析。

Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A Comprehensive Meta-analysis.

出版信息

Curr Probl Cardiol. 2021 Mar;46(3):100695. doi: 10.1016/j.cpcardiol.2020.100695. Epub 2020 Aug 28.

Abstract

The presence of concurrent chronic total occlusion (CTO) is a strong predictor for both short-term and long-term mortality. Successful percutaneous coronary intervention (PCI) of CTO has been associated with clinical benefit. We sought to perform a meta-analysis comparing CTO-PCI versus optimal medical therapy. PubMed, ClinicalTrials.gov, Google scholar and the Cochrane Central Register of Controlled Trials were searched for studies published from 2006 to 2019. A total of 16 studies, with 11,314 patients were included. We analyzed data on mortality, cardiac deaths, myocardial re-infarction, major adverse cardiac events, stroke, and repeat CTO-PCI using random-effects models. The odds ratios (OR) with 95% confidence interval (CI) were computed and P < 0.05 was considered as a level of significance. Compared with medical therapy alone, CTO-PCI was associated with lower mortality (OR: 0.45, CI: 0.32-0.63, P < 0.00001) and cardiac deaths (OR: 0.58, CI: 0.38-0.89, P = 0.01). These results were primarily driven by observational studies with no difference observed in randomized controlled trials. There was no significant difference in the incidence of major adverse cardiac events (OR: 0.71, CI: 0.48-1.05, P = 0.54), myocardial re-infarction (OR: 0.71, CI: 0.48-1.05, P = 0.54), stroke (OR: 0.61, CI: 0.32-1.17, P = 0.14, and repeat PCI (OR: 1.28, CI: 0.91-1.78, P = 0.16). This meta-analysis shows lower long-term mortality and cardiac deaths in CTO-PCI group as compared to OMT driven by observational studies with no difference observed in randomized controlled trials. Further randomized trials are needed to confirm these findings and evaluate long term results.

摘要

同时存在慢性完全闭塞(CTO)是短期和长期死亡率的强烈预测因素。成功进行经皮冠状动脉介入治疗(PCI)CTO 与临床获益相关。我们试图进行一项荟萃分析,比较 CTO-PCI 与最佳药物治疗。从 2006 年到 2019 年,我们在 PubMed、ClinicalTrials.gov、Google Scholar 和 Cochrane 对照试验中心注册处搜索了已发表的研究。共纳入 16 项研究,共 11314 例患者。我们使用随机效应模型分析了死亡率、心脏死亡、心肌再梗死、主要不良心脏事件、卒中和重复 CTO-PCI 的数据。计算了比值比(OR)及其 95%置信区间(CI),P<0.05 被认为是显著性水平。与单独药物治疗相比,CTO-PCI 与较低的死亡率(OR:0.45,CI:0.32-0.63,P<0.00001)和心脏死亡(OR:0.58,CI:0.38-0.89,P=0.01)相关。这些结果主要由观察性研究驱动,随机对照试验中没有观察到差异。主要不良心脏事件(OR:0.71,CI:0.48-1.05,P=0.54)、心肌再梗死(OR:0.71,CI:0.48-1.05,P=0.54)、卒中和重复 PCI(OR:0.61,CI:0.32-1.17,P=0.14,OR:1.28,CI:0.91-1.78,P=0.16)的发生率无显著差异。这项荟萃分析表明,与 OMT 相比,CTO-PCI 组的长期死亡率和心脏死亡率较低,这主要由观察性研究驱动,随机对照试验中没有观察到差异。需要进一步的随机试验来证实这些发现并评估长期结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验